Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Crohn's Disease AND Colitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    158 result(s) found for: Crohn's Disease AND Colitis. Displaying page 5 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2014-001919-39 Sponsor Protocol Number: 48890 Start Date*: 2014-08-27
    Sponsor Name:Erasmus MC
    Full Title: Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study
    Medical condition: Inflammatory bowel disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001410-10 Sponsor Protocol Number: GIS-SUSANTI-TNF-2015 Start Date*: 2016-06-22
    Sponsor Name:Fundación de Investigación Biomédica Hospital Universitario de la Princesa
    Full Title: Anti-TNF discontinuation in patients with inflammatory bowel disease: Multicentre, prospective, randomized clinical trial and economic evaluation
    Medical condition: Inflammatory bowel disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10021973 Inflammatory bowel disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001546-33 Sponsor Protocol Number: RHMMED1526 Start Date*: 2018-07-11
    Sponsor Name:University Southampton Hospital NHS Foundation Trust
    Full Title: IBD Biosimilar to Biosimilar Infliximab Switching Study
    Medical condition: Inflammatory Bowel Disease in particular Crohn's Disease and Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10021972 Inflammatory bowel disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003966-34 Sponsor Protocol Number: A12-771 Start Date*: 2011-12-06
    Sponsor Name:Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
    Full Title: The ADACAL Study: cAlprotectin and hsCRP as markers of a new Diagnostic-therapeutic strAtegy that assesses muCosal Activity to individuaLize treatment and improve the prognosis of patients with Cro...
    Medical condition: Crohn's disease (CD) is an inflammatory disease of the intestines that primarily causes abdominal pain, diarrhea, vomiting, or weight loss.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004325-10 Sponsor Protocol Number: ME/2005/2018 Start Date*: 2005-08-16
    Sponsor Name:United Bristol Healthcare Trust
    Full Title: Evaluate Whether A Short Course Of Once Weekly Risedronate Prevents Bone Loss Following High-Dose Steroid Therapy For An Acute Exacerbation Of Inflammatory Bowel Disease.
    Medical condition: We aim to determine whether Risedronate is effective at preventing acute bone loss associated with a short course of corticosteroid (CS) therapy to treat exacerbations of inflammatory bowel disease...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022758-18 Sponsor Protocol Number: CNTO1275CRD3001 Start Date*: 2011-08-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severe...
    Medical condition: Moderately to severely active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) BE (Completed) CZ (Completed) IS (Completed) IE (Completed) ES (Completed) DK (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007519-34 Sponsor Protocol Number: FAST VERSION Start Date*: 2009-04-17
    Sponsor Name:University of Leuven Hospitals, Division of Gastroenterology
    Full Title: Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST
    Medical condition: This is a open label, prospective, multicenter trial in patients recieving one hour infusions of infliximab (i.e. Remicade)as part of their daily practice. Main objective: Is to assess the tolerab...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002640-27 Sponsor Protocol Number: GED-301-01-11 Start Date*: 2011-07-14
    Sponsor Name:GIULIANI
    Full Title: A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn‟s disease (Ileo-Colitis)
    Medical condition: ACTIVE CROHN'S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10021315 Ileitis terminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004463-25 Sponsor Protocol Number: RHMMED1716 Start Date*: 2020-12-15
    Sponsor Name:University Hospital Southampton NHS Trust
    Full Title: SWitching InflixiMab to SUbcut from Intravenous Therapy
    Medical condition: Crohn's Disease Ulcerative Colitis Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-002369-17 Sponsor Protocol Number: 2021-01 Start Date*: 2021-07-22
    Sponsor Name:GETAID
    Full Title: Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial, the POMEROL trial.
    Medical condition: Crohn's disease patients having an i2 endoscopic postoperative recurrence 6-12 months after ileocolonic anastomosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002783-33 Sponsor Protocol Number: C13007 Start Date*: 2009-03-02
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Dise...
    Medical condition: Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) HU (Completed) SK (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) IS (Completed) PT (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) MT (Completed) GB (Completed) BG (Completed) SE (Completed) IT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002211-65 Sponsor Protocol Number: GIS-2021-JAKihemo Start Date*: 2021-08-13
    Sponsor Name:Fundación Española de Gastroenterología
    Full Title: EFFECT OF TOFACITINIB ON COAGULATION AND PLATELET FUNCTION, AND ITS ROLE IN THROMBOEMBOLIC EVENTS
    Medical condition: ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.0 10022891 - Investigations 10009790 Coagulation time PT
    21.0 10022891 - Investigations 10061684 Platelet function test PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001377-28 Sponsor Protocol Number: 27577 Start Date*: 2008-06-11
    Sponsor Name:Merck Serono International S.A.
    Full Title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of...
    Medical condition: Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061664 Autoimmune disorder LLT
    9.1 10025139 Lupus erythematosus systemic LLT
    9.1 10047888 Wegener's granulomatosis LLT
    9.1 10002817 Antiphospholipid syndrome LLT
    9.1 10040767 Sjogren's syndrome LLT
    9.1 10039073 Rheumatoid arthritis LLT
    9.1 10028245 Multiple sclerosis LLT
    9.1 10045228 Type I diabetes mellitus LLT
    9.1 10011401 Crohn's disease LLT
    9.1 10009900 Colitis ulcerative LLT
    9.1 10003827 Autoimmune hepatitis LLT
    9.1 10049046 Autoimmune thyroiditis LLT
    9.1 10003822 Autoimmune haemolytic anaemia NOS LLT
    9.1 10034697 Pernicious anemia LLT
    9.1 10028417 Myasthenia gravis LLT
    9.1 10018620 Goodpasture's syndrome LLT
    9.1 10018766 Guillain Barre syndrome LLT
    9.1 10043554 Thrombocytopenia LLT
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-005086-39 Sponsor Protocol Number: BT-11-201 Start Date*: 2019-10-28
    Sponsor Name:Landos Biopharma Inc.
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis
    Medical condition: Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifesta...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) HR (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004219-29 Sponsor Protocol Number: 140041 Start Date*: 2020-04-21
    Sponsor Name:Amsterdam UMC
    Full Title: “Personalized AZithromycin/metronidAZole, in combination with standard induction therapy, to achieve a fecal microbiome community structure and metagenome changes associated with sustained remissio...
    Medical condition: Crohn's Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001924-40 Sponsor Protocol Number: GED-0301-CD-003 Start Date*: 2017-02-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with act...
    Medical condition: Active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016693 10021315 Ileitis terminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004313-15 Sponsor Protocol Number: NI-0401-01 Start Date*: 2006-07-14
    Sponsor Name:NovImmune S.A.
    Full Title: A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease
    Medical condition: Moderate to Severe Active Crohn´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005059-10 Sponsor Protocol Number: Trp-IBD Start Date*: 2018-09-14
    Sponsor Name:Ghent University Hospital
    Full Title: Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores
    Medical condition: Inflammatory Bowel Disease (IBD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006881-19 Sponsor Protocol Number: TV48574-IMM-20036 Start Date*: 2022-12-21
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerat...
    Medical condition: Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.0 100000004856 10011400 Crohn's colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) AT (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004012-10 Sponsor Protocol Number: MODIFI Start Date*: 2021-06-17
    Sponsor Name:UZ Leuven
    Full Title: Model-informed infliximab dose de-escalation following earlier dose escalation in adult patients with inflammatory bowel diseases
    Medical condition: Inflammatory bowel diseases - Crohn's disease - ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 07 17:40:42 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA